Posted in | Bionanotechnology

Dolomite Collaboration Results in an Instrument for Detecting Circulating Tumour Cells

Published on November 22, 2011 at 7:58 PM

Microfluidics expert, Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

The innovative ClearCell System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.

The ClearCell™ System.

Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, "We are excited to be working with an innovative company like Clearbridge BioMedics. The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science. By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the Microfluidics expert, Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

The innovative ClearCell System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.

Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, "We are excited to be working with an innovative company like Clearbridge BioMedics. The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science. By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the novel field of automated capture of viable CTCs. We are looking forward to extending our partnership beyond research tools and into the clinical diagnostic domain."

"We see microfluidics playing an increasing key role in many Companion Diagnostics and In-Vitro Diagnostics devices. Dolomite has demonstrated that they are indeed a leader in this field, and we look forward to developing our future platform devices and systems together", commented Johnson Chen, Managing Director of Clearbridge BioMedics.

For further information on Dolomite's instrument development solutions as well as the complete portfolio of microfluidic products including chips, connectors/ interconnects, pumps, valves and custom devices please visit www.dolomite-microfluidics.com.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit